One year into EU Joint Clinical Assessment: Operational, but still unproven in practice
Joint Clinical Assessment (JCA) came into force in January 2025. One year on, real-world experience remains…
Category Research Insights
Pre-launch asset valuation: When BD&L need speed and Early Pipeline need depth
Two scenarios, both requiring pre-launch asset valuation: Scenario 1: Your BD&L team is evaluating a licensing…
Value-based pricing approaches for oncology products in Germany
Value-based pricing for oncology products in Germany requires a different approach to pre-launch price forecasting. GPI…
When traditional pricing methods fail: how Analogue Benchmarking solves the orphan drug pricing challenge
Phase 3 investment decisions for rare disease assets represent tens of millions in committed capital. Yet…
Analogue benchmarking for orphan drug pricing
Analogue benchmarking for orphan drug pricing solves the problem that stops traditional methods in their tracks:…
Bridging the gap: Pharmaceutical pricing and the urgent need for equitable access to medicines in low- and middle-income countries
With the increasing demand for high-cost, innovative medicines, low- and middle-income countries (LMICs) are facing even greater…
NICE threshold increase: the strategic questions your pricing team should be asking
Yesterday, the UK government announced a major change in pharmaceutical pricing policy. NICE’s cost-effectiveness threshold will…
Evidence Generation Planning
Evidence of all types, from real-world and clinical to HEOR and patient experience, is essential to…
Humira as a Benchmark: What GPI Data Reveals About Biosimilar Pricing and Originator Price Erosion in Europe
Introduction In the coming years, the pharmaceutical market is expected to see a significant influx of…
